Unknown

Dataset Information

0

Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study.


ABSTRACT: OBJECTIVE:This study was done to evaluate whether perioperative propranolol (ß-blocker) in ovarian cancer patients undergoing debulking surgery reduced perioperative tumor growth induced by surgical stress. METHODS:This was a prospective randomized single institution analysis. The primary objective was to compare the changes in CA 125 level (changes between preoperation day 2 and postoperative day 7). As a study arm, patients received a low dose of propranolol 40 mg/day (4×10 mg) starting two days before surgery and 40 mg twice daily for three days following surgery. RESULTS:Twenty-two patients were enrolled and 16 were evaluable for efficacy. The drug was well tolerated. The mean decrease of CA 125 during the seven perioperative days was 83.1±8.9% in the propranolol group and 72.4±14.7% in the placebo group. The difference was statistically significant (P=0.044). The change of C-reactive protein, cortisol, and anxiety score (State-Trait Anxiety Inventory-X1) were not different between the two groups. CONCLUSION:This preliminary result is the first to directly test the role of perioperative propranolol on tumor growth. Even with the small sample size and short term use of the drug, perioperative propranolol was effective in reducing tumor burden (as measured by CA 125) suggesting its potential benefits in decreasing perioperative tumor growth.

SUBMITTER: Jang HI 

PROVIDER: S-EPMC5364099 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study.

Jang Hye-In HI   Lim Soo-Hyun SH   Lee Yoo-Young YY   Kim Tae-Joong TJ   Choi Chel Hun CH   Lee Jeong-Won JW   Kim Byoung-Gie BG   Bae Duk-Soo DS  

Obstetrics & gynecology science 20170316 2


<h4>Objective</h4>This study was done to evaluate whether perioperative propranolol (ß-blocker) in ovarian cancer patients undergoing debulking surgery reduced perioperative tumor growth induced by surgical stress.<h4>Methods</h4>This was a prospective randomized single institution analysis. The primary objective was to compare the changes in CA 125 level (changes between preoperation day 2 and postoperative day 7). As a study arm, patients received a low dose of propranolol 40 mg/day (4×10 mg)  ...[more]

Similar Datasets

| S-EPMC4469531 | biostudies-literature
| S-EPMC8730356 | biostudies-literature
| S-EPMC6408081 | biostudies-literature
| S-EPMC7772940 | biostudies-literature
| S-EPMC10090366 | biostudies-literature
| S-EPMC3269116 | biostudies-literature
| S-EPMC4060250 | biostudies-literature
| S-EPMC5473574 | biostudies-literature
| S-EPMC4972341 | biostudies-literature
| S-EPMC5484072 | biostudies-literature